Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis

M.Aapro; M.Schwenkglenks; G.Lyman; A.Lopez-Pousa; P.Bacon; S.Lawrinson; G.Von Minckwitz

首页> 外文期刊>European Journal of Cancer Supplements >Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis

【24h】

Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis

机译：接受pegfilgrastim一级预防与目前实践中性粒细胞减少症管理的乳腺癌患者的发热性中性粒细胞减少症风险随年龄和疾病阶段的变化而变化–来自NeuCuP分析的结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2008年第7期|共2页
作者
M.Aapro; M.Schwenkglenks; G.Lyman; A.Lopez-Pousa; P.Bacon; S.Lawrinson; G.Von Minckwitz;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis [J] . M.Aapro, M.Schwenkglenks, G.Lyman, European Journal of Cancer Supplements . 2008,第7期

机译：接受pegfilgrastim一级预防与目前实践中性粒细胞减少症管理的乳腺癌患者的发热性中性粒细胞减少症风险随年龄和疾病阶段的变化而变化–来自NeuCuP分析的结果
2. 2033 ORAL Improved chemotherapy delivery in breast cancer patients receiving pegfilgrastim primary prophylaxis compared with current practice neutropenia management – results from an integrated analysis (NeuCuP) [J] . M.Aapro, M.Schwenkglenks, G.Lyman, European Journal of Cancer Supplements . 2007,第4期

机译：2033 ORAL与目前的中性粒细胞减少症管理相比，接受培格非司亭主要预防措施的乳腺癌患者化疗方案的改善-一项综合分析（NeuCuP）的结果
3. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. [J] . von-Minckwitz G, Schwenkglenks M, Skacel T, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2009,第4期

机译：接受pegfilgrastim一级预防与目前中性粒细胞减少症管理的乳腺癌患者的发热性中性粒细胞减少症及相关并发症：综合分析的结果。
4. The Natural History of Chronic Kidney Disease Revisited-A 72-Month Mayo Health System Hypertension Clinic Practice-Based Research Network Prospective Report on End-Stage Renal Disease and Death Rates in 100 High-Risk Chronic Kidney Disease Patients: A Call for Circumspection [C] . Macaulay A.C. Onuigbo Conference on Peritoneal Dialysis . 2009

机译：慢性肾病的自然历史重新审议-A 72个月的MASO卫生系统高血压诊所的研究网络网络前期肾病和死亡率100个高危慢性肾病患者的死亡率：一个呼吁守则
5. Effects of primary prophylaxis of neutropenia on outcomes, utilization and expenditures for elderly breast cancer patients receiving chemotherapy. [D] . Rajan, Suja S. 2009

机译：一级预防中性粒细胞减少对老年接受化疗的乳腺癌患者的结局，利用和支出的影响。
6. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel cisplatin and 5-fluorouracil [O] . Yu Ohkura, Masaki Ueno, Harushi Udagawa 2019

机译：多西他赛顺铂和5-氟尿嘧啶治疗的食管癌患者发热性中性粒细胞减少的危险因素和培格非司亭预防性治疗的有效性
7. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy [O] . Aapro, M, Schwenkglenks, M, Lyman, G H, 2010

机译：接受化疗的老年乳腺癌患者接受Pegfilgrastim的初步预防与目前的中性粒细胞减少管理
8. Psychological Stress, Neutropenia and Infectious Disease in Patients Receiving Chemotherapy Treatment for Breast Cancer [R] . Bovbjerg, D. 1999

机译：乳腺癌化疗治疗患者的心理应激，中性粒细胞减少和传染病

Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis

著录项

相似文献

相关主题

期刊订阅